Get the Stockscreener App
34.26
0.03%
-0.01
Viking Therapeutics Inc stock is traded at $34.26, with a volume of 2.84M.
It is down -0.03% in the last 24 hours and up +3.88% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$34.27
Open:
$34.03
24h Volume:
2.84M
Relative Volume:
0.56
Market Cap:
$3.87B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-36.84
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
-12.40%
1M Performance:
+3.88%
6M Performance:
+25.72%
1Y Performance:
-33.64%
1-Day Range:
$32.90
$34.93
1-Week Range:
$32.90
$38.75
52-Week Range:
$18.92
$56.25
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
34.26 | 3.87B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-25 | Initiated | Canaccord Genuity | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Goldman | Neutral |
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Viking Therapeutics Stock: Clinical Trial Momentum Builds Substantial Upside - Ad-hoc-news.de
Viking Therapeutics Stock: A Turning Point Emerges - Ad-hoc-news.de
2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon - The Motley Fool
Viking Therapeutics Stock: A Transformative Week for the Biotech Firm - Ad-hoc-news.de
What drives Viking Therapeutics Inc stock priceStock Price Divergence & Low Cost Portfolio Tips - earlytimes.in
Viking Therapeutics (VKTX) Up 1% Since Last Earnings Report: Can It Continue? - sharewise.com
Will Viking Therapeutics Inc. (1VT) stock deliver compounding returnsOil Prices & Fast Exit/Entry Strategy Plans - newser.com
Viking Therapeutics concludes enrolment in Phase III trial of obesity therapy - Clinical Trials Arena
3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential - Finviz
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug - Yahoo Finance
How (VKTX) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Viking Therapeutics stock holds Buy rating as obesity trial enrollment completes - Investing.com India
Is Viking Therapeutics Inc. stock a top momentum playBull Run & Technical Pattern Recognition Alerts - newser.com
Using Bollinger Bands to evaluate Viking Therapeutics Inc.Product Launch & Reliable Entry Point Alerts - newser.com
Can Viking Therapeutics Inc. (1VT) stock sustain margin levelsWeekly Trade Review & Capital Protection Trading Alerts - newser.com
Viking Therapeutics, Up 62% Since August, Undercuts A Buy Zone Despite Key Win - Investor's Business Daily
Can Viking Therapeutics Inc. stock reach $100 price target2025 Top Decliners & Daily Profit Focused Stock Screening - newser.com
Viking therapeutics completes enrollment in obesity drug trial By Investing.com - Investing.com Nigeria
William Blair Reiterates “Buy” Rating on Viking Therapeutics (VKTX) Following New VK2735 Data - MSN
Why Viking Therapeutics Inc. (1VT) stock attracts HNW investorsJuly 2025 Decliners & Fast Exit and Entry Strategy Plans - newser.com
Why Viking Therapeutics Inc. stock could see breakout soonJuly 2025 Institutional & Accurate Technical Buy Alerts - newser.com
How to Invest in Viking Therapeutics (VKTX) - The Motley Fool
Viking Therapeutics : November 2025 Corporate Presentation - MarketScreener
Strong Enrollment and Promising Strategy Propel Viking Therapeutics to ‘Buy’ Rating - TipRanks
Viking Therapeutics (VKTX) Stock: Investors Eye 78-Week Readout After Ahead-of-Schedule Phase 3 Progress - parameter.io
Viking Therapeutics, Up 62% Since August, Lingers In Buy Zone On An Obesity Win - MSN
Viking: Playfield Has Changed, Downgrading To Hold After A Strong Run (NASDAQ:VKTX) - Seeking Alpha
Promising Potential of Viking Therapeutics’ VK2735 Justifies Buy Rating - TipRanks
Is Viking Therapeutics Inc. stock a buy before product launchesInflation Watch & Technical Pattern Based Buy Signals - newser.com
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. - AOL.com
Viking Therapeutics (VKTX) Completes Enrollment for Key Phase 3 Trial - GuruFocus
What consensus target says about Viking Therapeutics Inc. (1VT) stockOil Prices & Capital Protection Trade Alerts - newser.com
Why Viking Therapeutics Inc. stock is popular among millennialsMarket Trend Summary & Verified Swing Trading Watchlists - newser.com
Viking Therapeutics at Jefferies: Strategic Insights on Obesity Drug By Investing.com - Investing.com India
Viking Therapeutics at Jefferies: Strategic Insights on Obesity Drug - Investing.com
Viking Therapeutics Completes Enrollment in Phase 3 Vanquish 1 Obesity Trial - MarketScreener
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 - Finviz
Viking therapeutics completes enrollment in obesity drug trial - Investing.com India
Stocks To Watch: Viking Therapeutics Sees Relative Strength Rating Rise To 89 - Investor's Business Daily
Viking Therapeutics (VKTX) completes VANQUISH-1 obesity trial for 4,650 adults - Stock Titan
Signal strength of Viking Therapeutics Inc. stock in tech scannersChart Signals & Capital Protection Trade Alerts - newser.com
What makes Viking Therapeutics Inc. stock attractive to growth fundsJuly 2025 Reactions & Intraday High Probability Setup Alerts - newser.com
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):